<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Laboratory observations suggest that, in some <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), immune mechanisms may contribute to the impaired blood cell production </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha), a potent inhibitor of haematopoiesis, has been hypothesized to mediate suppressive effects in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: TNF-alpha levels are elevated and correlated with marrow <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cytopenia </plain></SENT>
<SENT sid="2" pm="."><plain>Inhibition of TNF-alpha production using the soluble TNF receptor (Enbrel) has been successful in <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, and we have now applied the same principle to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We determined spontaneous TNF-alpha production by marrow cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; TNF-alpha production was elevated (&gt; mean + 2 x SD of controls) in &gt; 1/3 of patients, but did not correlate with clinical parameters </plain></SENT>
<SENT sid="4" pm="."><plain>Sixteen patients participated in a 3-month pilot study of Enbrel </plain></SENT>
<SENT sid="5" pm="."><plain>The drug was well tolerated and 15 patients were evaluable </plain></SENT>
<SENT sid="6" pm="."><plain>Of these, one became temporarily (14 weeks) transfusion independent </plain></SENT>
<SENT sid="7" pm="."><plain>In another patient, absolute neutrophil count (ANC) rose from 0.5 x 10(9)/l to 0.84 x 10(9)/l </plain></SENT>
<SENT sid="8" pm="."><plain>Serious <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were seen in two out of six neutropenic patients </plain></SENT>
<SENT sid="9" pm="."><plain>Progression to refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts in transformation (RAEBt) or <z:mpath ids='MPATH_336'>leukaemia</z:mpath> was observed in three patients </plain></SENT>
<SENT sid="10" pm="."><plain>When the effects of Enbrel on haematopoietic colony formation were studied, no significant increase was seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and there was no correlation with TNF-alpha levels </plain></SENT>
<SENT sid="11" pm="."><plain>Although anti-TNF therapy with Enbrel was well tolerated at the dosages used in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, its efficacy as a single agent appears low </plain></SENT>
</text></document>